Evotec`s PanHunter Receives Honorable Mention in the Software Category of Fast Company’s 2023 World Changing Ideas Awards
Hamburg, Germany, 16. May 2023
The winners of Fast Company’s 2023 World Changing Ideas Awards were announced today, honoring sustainable designs, innovative products, bold social initiatives, and other creative projects that are changing the way we work, live, and interact with the world.
PanHunterTM, Evotec’s multi-omics data access and analytics platform, received Honorable Mention in the Software Category of Fast Company’s 2023 World Changing Ideas Awards, honoring Evotec’s commitment towards patient-centric, PanOmics-driven drug discovery. PanHunter contributed to Evotec’s success in industry-shaping drug discovery partnerships over years. PanHunter is available to collaborators and partners as a software-as-a-service (“SaaS”) product enabling them to handle the exponentially growing amount of available PanOmics data in the public domain and in the pharmaceutical industry.
This year’s World Changing Ideas Awards showcase 45 winners, 216 finalists, and more than 300 honorable mentions—with health, climate, energy, software and AI among the most popular categories.
Among these are some of the world’s most inventive entrepreneurs and forward-thinking companies that are actively tackling global challenges.
A panel of Fast Company editors and reporters selected winners and finalists from a pool of more than 2,200 entries across urban design, education, nature, politics, technology, corporate social responsibility, and more.
Dr Erik Schliep, said: “I am very excited to see our software platform PanHunter being honored by the Fast Company’s 2023 World Changing Ideas Awards, as it approves our path towards large scale omics driven drug discovery: The fight against incurable diseases can only be won if we equip our scientists with the necessary software tools that greatly accelerate and simplify the interpretation of omics data. This is a fundamental building block in fulfilling our mission to find medicines that matter and shortening the overall time to develop them.”